Total
0
Shares
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Leading digital health company ResApp Health (RAP) has received firm commitments to raise $5.5 million through a placement
  • The company will issue over 94 million shares at 5.8 cents per share to institutional and sophisticated investors
  • Funds from the placement will be used to provide ResApp with the financial flexibility to progress a number of initiatives
  • Existing shareholder Fidelity International has agreed to invest $1.5 million, increasing its shareholding to 9.99 per cent
  • Just before the market opens, ResApp traded at 6.8 cents per share

ResApp Health (RAP) has received firm commitments to raise $5.5 million through a placement.

The company will issue over 94 million shares at 5.8 cents per share to institutional and sophisticated investors.

Funds from the placement will be used to provide ResApp with the financial flexibility to progress a number of initiatives. These includes hiring key personnel and allowing the company to grow its commercial partnership pipeline.

Existing substantial shareholder, Fidelity International, has agreed to cornerstone the placement with $1.5 million investment. Once the placement completes, Fidelity International will hold 9.99 per cent of ResApp.

CEO and Managing Director Dr Tony Keating is pleased to have generated such a strong interest in the placement.

"I would like to welcome a number of new institutional investors to our
register and also express our thanks to our existing shareholders who have continued to support the company," he said.

"Funds secured from the placement will provide ResApp with a very solid footing to execute on our commercial strategy in telehealth and emerging markets, continue to innovate in areas such as COVID-19 screening and management, and further expand the opportunity to provide solutions to large pharmaceutical companies for clinical trials and disease management," he added.

Just before the market opens, ResApp traded at 6.8 cents per share.

RAP by the numbers
More From The Market Herald
Immutep (ASX:IMM) - CEO, Marc Voigt - The Market Herald

" Immutep (ASX:IMM) progresses multiple efti trials

Immutep (IMM) has provided an update on its clinical and preclinical programs.
PolyNovo (ASX:PNV) dispatches first NovoSorb BTM order in Europe

" Polynovo (ASX:PNV) appoints Joshua Cheetam as Director of Research and Development

PolyNovo (PNV) has appointed Dr Joshua Cheetam as Director of Research and Development.
The Market Herald Video

" Regeneus (ASX:RGS) secures $4.5 M for osteoarthritis trials

Clinical-stage regenerative medicine company Regeneus (RGS) has secured up to $4.5 million in a three-stage placement of the company’s shares to New Lif…
Xped (ASX:XPE) appoints Con Unerkov as CEO

" Flexiroam (ASX:FRX) leadership shuffle to underpin further growth

Mobile data provider Flexiroam (FRX) has announced several changes to the company’s board and leadership.